No Data
No Data
No Data
No Data
No Data
Prelude Therapeutics: Leading the Oncology Market With Innovative SMARCA2 Targeting Drug PRT3789
TipRanksApr 25 14:05 ET
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
Simply Wall StApr 15 09:45 ET
Several Insiders Invested In Prelude Therapeutics Flagging Positive News
Yahoo FinanceApr 13 09:54 ET
Prelude Therapeutics Announces CFO Transition and Interim Appointment
TipRanksApr 10 16:24 ET
Express News | Prelude Therapeutics Disclosed Laurent Chardonnet Will No Longer Serve As CFO
Moomoo 24/7Apr 10 16:11 ET
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527,
GlobeNewswireApr 9 16:35 ET
No Data
No Data